ECAT to hold a series of online meetings with pharmaceutical companies

As part of its annual activities, the Eurasian Community for Access to Treatment (ECAT) will organize several online meetings with pharmaceutical companies to discuss issues related to the registration, pricing, and availability of essential medicines in Eastern Europe and Central Asia (EECA).

For autumn 2025, Zoom calls have already been confirmed with the following companies:

• Otsuka

  The main focus will be on delamanid. We plan to address issues related to the registration of the medicine in the region, the company’s pricing policy, and prospects for expanding access for patients in need of tuberculosis treatment.

• Gilead

  The key topic will be lenacapavir. The discussion will also cover the registration of the medicine in EECA countries, timelines for market entry, as well as the company’s plans regarding the introduction of generics and ensuring patient access.

• Merck (MSD)

  The dialogue will focus on three areas: HIV prevention, including the company’s new development — a once-monthly tablet for pre-exposure prophylaxis (PrEP); vaccination against human papillomavirus (HPV), including the Gardasil vaccine; and medicines for the treatment of cervical cancer.

• Viatris

  The focus will be on the company’s role in ensuring access to generics in the region. We plan to discuss supply chain sustainability, as well as new products that the company may introduce in EECA countries.

In addition, we are awaiting confirmation of meetings with several other pharmaceutical companies, which will be announced later. Following the meetings, reports will be published in both Russian and English.